Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma-Reference-Cited by-同舟云学术

Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma

Published:2018-06-12 Issue:21 Volume:24 Page:5233-5238
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Chi Yihebali,Fang Zhiwei,Hong Xiaonan,Yao Yang,Sun Ping,Wang Guowen,Du Feng,Sun Yongkun,Wu Qiong,Qu Guofan,Wang Shusen,Song Jianmin,Yu Jianchun,Lu Yongkui,Zhu Xia,Niu Xiaohui,He Zhiyong,Wang Jinwan,Yu Hao,Cai Jianqiang

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 238 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fibroblast Growth Factor 2 (FGF2) Activates Vascular Endothelial Growth Factor (VEGF) Signaling in Gastrointestinal Stromal Tumors (GIST): An Autocrine Mechanism Contributing to Imatinib Mesylate (IM) Resistance;Cancers;2024-09-07

2. Shedding light on pancreatic metastasis of clear cell sarcoma: An exceptional journey;World Journal of Clinical Cases;2024-09-06

3. Real-world efficacy, safety data and predictive clinical parameters for treatment outcomes in advanced soft tissue sarcoma treated with combined immunotherapy and antiangiogenic therapy;BMC Cancer;2024-08-20

4. Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis;Frontiers in Immunology;2024-08-14

5. Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study;Cancer Immunology, Immunotherapy;2024-08-06